Shanghai and San Diego – December 14, 2017: WuXi Biologics (WuXi Biologics, 2269.HK), a global leading biopharmaceutical technology platform company, and Phanes Therapeutics, located in the Songshan Lake High-tech Zone in Guangdong, China, and San Diego, USA, announced today thatThe two parties formally signed a memorandum of cooperation to establish a close strategic partnership in the research, development, and manufacturing of biologics.
▲ Dr. Chen Zhisheng, CEO of WuXi Biologics, and Dr. Wang Minghan, President and CEO of Phanes Therapeutics, jointly attended the signing ceremony of the “Memorandum of Understanding between WuXi Biologics and Phanes Therapeutics” held in Shanghai
Under the collaboration agreement, WuXi Biologics will become the global partner for Phanes Therapeutics Inc. in the clinical manufacturing of multiple innovative biologics worldwide, and will also serve as the preferred partner for the research, development, and manufacturing of Phanes’ future innovative biologics.
Dr. Wang Minghan, President and Chief Executive Officer of Phanes Therapeutics, expressed his warm welcome for this collaboration: “As an innovative drug development company with a robust R&D pipeline, we require a top-tier CMC platform to rapidly advance our lead molecules. We are delighted to establish a strategic partnership with WuXi Biologics, which boasts an exceptional CMC platform and has a strong track record in delivering high-quality GMP samples.”WuXi Biologics’ biologics CMC platform is a perfect match for Phanes Therapeutics, enabling Phanes to continue focusing on what it does best—innovative R&D.We look forward to establishing a productive partnership.”
“We are honored to have the opportunity to collaborate closely with global innovative biotechnology companies such as Phanes Therapeutics, working together to rapidly advance their multiple R&D projects into clinical trial stages,” said Dr. Chen Zhisheng, CEO of WuXi Biologics. “Leveraging WuXi Biologics’ world-class, high-quality, integrated biologics R&D platform, both parties will bring more life-saving innovative biologics that are accessible and affordable to patients in global markets, thereby benefiting patients worldwide.”
About Phanes Therapeutics
Phanes Therapeutics is a biotechnology company with extensive expertise in metabolic complications and oncology. Founded by Dr. Wang Minghan, former Vice President of Johnson & Johnson, the company focuses on the research and development of biologics, with multiple first-in-class molecules in its pipeline. For more information, please visit: www.phanesthera.com.
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is a globally leading open, integrated biologics technology and manufacturing platform. The Company provides comprehensive end-to-end research and development services to global biopharmaceutical and biotechnology companies, empowering individuals and organizations to discover, develop, and manufacture biologics. By enabling the entire process from concept to commercial-scale production, WuXi Biologics accelerates the global R&D of biologics, reduces development costs, and ultimately benefits patients. For more information, please visit: www.wuxibiologics.com.cn.